Misleading Advertisements Land Two Drugmakers FDA Warning Letters

Drug Industry Daily
A A
The FDA’s Office of Prescription Drug Promotion (OPDP) issued warning letters to two companies for publishing misleading advertisements that omitted risks and exaggerated benefits.

To View This Article:

Login

Subscribe To Drug Industry Daily